Improving lives with liver disease care
Genfit (genfit.com) scores 83 out of 100 on Brand Analyzer, placing it in the Strong Brand tier among Healthcare brands, in the 90th percentile of 21634 Healthcare brands.
GENFIT is a biopharmaceutical company headquartered in Loos, France, focused on developing therapies for acute-on-chronic liver failure (ACLF) and other life-threatening liver diseases. The company combines internal research with strategic licensing partnerships, such as its collaboration with Ipsen, to advance drug development. GENFIT reports regular financial updates, including its cash position, reflecting its status as a publicly tracked biopharmaceutical innovator serving patients, healthcare providers, pharmaceutical partners, and investors.
| Brand Name | Genfit |
|---|---|
| Domain | genfit.com |
| Industry | Healthcare |
| Headquarters | Loos, France |
| Main Competitors | Intercept Pharmaceuticals (71/100), Madrigal Pharmaceuticals (83/100), Akero Therapeutics (74/100), CymaBay Therapeutics (82/100), 89bio (73/100), Ipsen (89/100) |
Moz Domain Authority 43/100 vs category average 40 / leader 95 - a strong backlink profile, so AI systems frequently encounter mentions of the brand.
Ranked #1,007,098 on the Tranco list of most-visited sites - modest traffic makes the brand easy for AI models to overlook.
No Wikipedia presence was found - a major gap, since Wikipedia is among the most heavily weighted sources in AI training data.
The homepage meta description reads "GENFIT Reports First-Half 2026 Financial Results and Provides Corporate Update Cash and cash equivalents totaled €113.8 million as of June 30," (Meta description: 22 words (ideal length). OG description present and descriptive) - this is the summary AI engines are most likely to quote.
Structured data on the homepage: 1 JSON-LD block(s), Organization schema, Breadcrumb/Website schema, og:title, og:description, og:image, og:type, Twitter cards, canonical. Adding FAQ schema would further help AI crawlers parse the brand's identity.
AI-crawler access: robots.txt present, no AI bot restrictions - robots.txt controls whether engines like GPTBot and ClaudeBot can read the site at all.
Detected tech stack: WordPress, Ghost.
Social footprint: verified profiles on LinkedIn, YouTube, Facebook, Instagram, GitHub; no detected presence on X (Twitter) - consistent profiles reinforce the brand's identity across the web.
0 Reddit mentions - community discussion signals real-world reputation to AI models.
Live results from asking a general-purpose AI assistant about the brand, checked October 2026.
When asked "What is Genfit?", Claude could identify the brand as of October 2026. Genfit is a French biopharmaceutical company focused on developing treatments for liver diseases, particularly NASH (non-alcoholic steatohepatitis) and other metabolic and liver-related conditions, including rare liver diseases like primary biliary cholangitis. Best known for Developing elafibranor and other drug candidates targeting NASH and liver diseases.
When asked "Best brands similar to Genfit?", Claude would recommend Genfit as of October 2026. It's a notable player in the liver disease and NASH treatment space, relevant if discussing biopharma companies working on metabolic liver conditions.
Common questions people ask in Google, ChatGPT, Claude, Gemini, Perplexity, and other AI search engines.
Genfit's main competitors in Healthcare: Intercept Pharmaceuticals (71/100), Madrigal Pharmaceuticals (83/100), Akero Therapeutics (74/100), CymaBay Therapeutics (82/100), 89bio (73/100).
Sources: Brand Analyzer scan
Genfit has limited AI-search visibility, scoring 38/100 on Brand Analyzer's AI visibility composite (visibility 23, trust 39, recommendation 62). This estimates how likely AI engines like ChatGPT, Claude, Gemini and Perplexity are to know, trust, and recommend the brand.
Sources: Genfit official site
Genfit scores 62/100 on Brand Analyzer's AI recommendation signal, indicating it is reasonably likely to be surfaced when AI assistants like ChatGPT suggest Healthcare options. Recommendation depends on crawlability, structured data, and category authority.
Sources: Genfit official site
GENFIT is a biopharmaceutical company based in Loos, France, dedicated to developing innovative therapies for severe liver diseases, including acute-on-chronic liver failure (ACLF).
Sources: Genfit official site
GENFIT conducts biopharmaceutical research and development aimed at creating treatments for life-threatening liver diseases, particularly ACLF. It also engages in strategic licensing partnerships, such as its agreement with Ipsen, to help accelerate the development and commercialization of its therapies.
Sources: Genfit official site
Genfit can improve AI discoverability by strengthening structured data (Organization and FAQ schema), maintaining an accurate Wikipedia/Wikidata entity, earning authoritative citations, and keeping content crawlable for AI bots. Brand Analyzer measures these as visibility, trust, and recommendation signals.
Sources: Genfit official site
GENFIT is known for its focus on developing treatments for ACLF and other severe liver diseases, as well as for its licensing partnership with Ipsen to support drug development and commercialization.
Sources: Genfit official site
GENFIT's work is intended to benefit patients suffering from ACLF and other severe liver diseases. Its broader audience includes healthcare providers who may administer its therapies, pharmaceutical partners like Ipsen involved in co-development or commercialization, and investors tracking its financial and clinical progress.
Sources: Genfit official site
Genfit scores 38/100 for AI visibility - how well ChatGPT, Claude, Perplexity and Google AI Overviews can discover, identify and cite the brand.
Genfit has a weak AI-visibility profile at 38/100 - a proxy for how readily ChatGPT, Perplexity and Google's AI Overviews can recognise and cite it. Its strongest area is recommendation likelihood (62/100) and its weakest is visibility (23/100). It benefits from a Wikidata knowledge-graph entry, a global traffic rank of #1,007,098 (Tranco) and a Moz Domain Authority of 43/100. The main gaps holding it back: no clear Wikipedia entity to anchor it in LLM training data and no llms.txt to steer AI to its best pages. In a live check, Claude could already identify Genfit from memory (October 2026) - a sign these signals are paying off.
The score combines seven dimensions - name quality, digital presence, visual identity, messaging clarity, trust foundation, AI discoverability, and brand authority - into a single objective benchmark.
Ranked closest to Genfit: Geneious (83/100), Genedata (83/100), Genmab (83/100), Gentherm (83/100).
A step up - brands to learn from: Zoetis (91/100), theSkimm (91/100).
Category leader: Booksy (96/100).
Brand Analyzer is built by DataEase AI. Track your brand in ChatGPT, Gemini and Perplexity.